Apyx Medical Corporation (NASDAQ:APYX) Short Interest Update

Apyx Medical Corporation (NASDAQ:APYX) was the target of a large increase in short interest in February. As of February 27th, there was short interest totaling 173,573 shares, an increase of 22.3% from the February 12th total of 141,982 shares. Based on an average trading volume of 64,528 shares, the short-interest ratio is currently 2.7 days. Approximately 0.5% of the shares of the stock are short sold. Approximately 0.5% of the shares of the stock are short sold. Based on an average trading volume of 64,528 shares, the short-interest ratio is currently 2.7 days.

Analysts Set New Price Targets

APYX has been the topic of several analyst reports. Wall Street Zen upgraded Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. Roth Mkm started coverage on Apyx Medical in a research report on Monday, December 15th. They set a “buy” rating and a $6.00 target price for the company. Craig Hallum boosted their price target on Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Zacks Research upgraded Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

Institutional Trading of Apyx Medical

Several institutional investors have recently added to or reduced their stakes in APYX. Millennium Management LLC bought a new position in Apyx Medical during the 4th quarter worth $324,000. 683 Capital Management LLC bought a new position in Apyx Medical during the fourth quarter worth about $436,000. ExodusPoint Capital Management LP bought a new stake in Apyx Medical in the 4th quarter valued at about $305,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Apyx Medical during the 4th quarter worth approximately $111,000. Finally, Nantahala Capital Management LLC grew its position in shares of Apyx Medical by 19.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock worth $13,909,000 after purchasing an additional 636,043 shares in the last quarter. 55.33% of the stock is currently owned by institutional investors.

Apyx Medical Trading Up 1.9%

Shares of NASDAQ:APYX opened at $3.74 on Wednesday. The firm has a market cap of $156.44 million, a price-to-earnings ratio of -13.85 and a beta of 1.61. The company’s fifty day simple moving average is $3.76 and its 200 day simple moving average is $3.37. Apyx Medical has a 12 month low of $0.76 and a 12 month high of $4.50. The company has a quick ratio of 4.26, a current ratio of 5.00 and a debt-to-equity ratio of 2.35.

Apyx Medical (NASDAQ:APYX) last announced its earnings results on Tuesday, March 10th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03. The business had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $19.12 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%. As a group, research analysts forecast that Apyx Medical will post -0.68 EPS for the current fiscal year.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.